A cystatin C test measures a blood protein that can be used to estimate glomerular filtration rate, or eGFR. It is generally less influenced by muscle mass than creatinine, making it useful when a creatinine-based estimate may be misleading. The combined creatinine–cystatin C estimate often improves accuracy, especially when a clinical decision depends on the result. NIDDK: adult eGFR equations.
Cystatin C is not a universal early-detection test, a direct GFR measurement, or a substitute for urine albumin testing. This guide focuses on adults and on choosing and interpreting a filtration estimate. Ulta Lab Tests offers related testing options; results should be reviewed with a qualified healthcare professional.
Cystatin C is a small protein produced by nucleated cells and filtered by the kidneys. Its blood concentration tends to rise as filtration decreases, but other influences can change it too. A Cystatin C with eGFR test provides the measured marker and a supported estimate; check the actual reporting details for the order. National Kidney Foundation: cystatin C.
The concentration is commonly reported in mg/L, while eGFR is usually reported in mL/min/1.73 m². These are different quantities. The laboratory reference interval describes the measured concentration, whereas an estimating equation incorporates the marker and patient variables. Neither a flag nor a number alone identifies why filtration may be reduced.
| Approach | Information used | Main consideration |
|---|---|---|
| Creatinine-based eGFR | Creatinine and the variables required by the equation | Widely used first estimate; muscle mass, diet, supplements, and some medicines can affect interpretation. |
| Cystatin C-based eGFR | Cystatin C and the variables required by the equation | Generally less affected by muscle mass; thyroid dysfunction, corticosteroids, inflammation, adiposity, and other non-GFR influences can matter. |
| Combined eGFR | Creatinine and cystatin C in a validated combined equation | Often improves average accuracy; remains vulnerable when one or both markers have substantial non-kidney influences. |
Creatinine is not an obsolete or “late-stage-only” test. It remains useful for initial assessment and trends. Cystatin C is most useful as complementary information, rather than as a reason to disregard a creatinine result automatically. Both markers need an appropriate clinical interpretation.
KDIGO recommends creatinine-based eGFR for initial assessment and combined creatinine–cystatin C estimation for GFR categorization in adults at risk for CKD when cystatin C is available. Added accuracy is particularly relevant when creatinine may be less reliable and the estimate affects a clinical decision. KDIGO, recommendations 1.1.2.1 and 1.2.2.1.
Symptoms such as fatigue, swelling, or foamy urine do not specifically indicate that cystatin C is the next test. They may require a broader clinical evaluation. Test selection should follow the question being investigated, not an assumption that every symptom calls for an advanced panel.
Corticosteroid exposure, thyroid dysfunction, inflammation, higher adiposity, smoking, and acute illness can complicate interpretation. The influence may differ from person to person and may affect creatinine and cystatin C differently. Discuss these factors with the clinician; do not change medication or thyroid treatment merely to alter a laboratory value. National Kidney Foundation: interpretation limitations.
Hydration and illness should not be dismissed just because a test uses cystatin C. Changes in circulating volume can change actual kidney filtration, not merely distort a laboratory marker. Acute kidney injury and rapidly changing filtration are especially difficult settings for steady-state estimating equations. A more precise-looking number does not eliminate that uncertainty.
When a strong non-GFR influence affects one marker, a clinician may rely more on the less-affected estimate or arrange measured GFR if sufficient accuracy cannot be obtained. The combined estimate is often better on average, but no equation is the best option for every individual circumstance. NIDDK: limitations of estimating equations.
First check the dates, units, equation, and whether both samples were obtained under comparable conditions. A difference between creatinine-based and cystatin C-based estimates does not prove that kidney function changed between tests. It may reflect different influences on the markers. Avoid selecting whichever number is more reassuring.
| Fictional example | What it may prompt | What it does not prove |
|---|---|---|
| Creatinine-based eGFR 52; combined eGFR 71 | Review of body composition, marker influences, and whether filtration classification should change. | That kidney disease has been cured or excluded; urine or structural findings may still matter. |
| Creatinine-based eGFR 52; combined eGFR 43 | Closer assessment of reduced filtration and factors affecting either marker. | That a particular treatment or medication dose is automatically required. |
| Preserved combined eGFR; persistently increased UACR | Evaluation of kidney damage despite preserved filtration. | That filtration testing replaces urine testing. |
The example values are educational and use mL/min/1.73 m² for eGFR. They are not calculated from invented patient concentrations. To assess chronic kidney disease, the clinician still considers persistence, cause, albuminuria, urine findings, and other clinical information. See the paired eGFR and urine albumin interpretation guide for the wider result framework.
There is no universal table in which one cystatin C concentration always means a particular eGFR or CKD stage. The estimate depends on the chosen equation and its required variables. Adult and pediatric equations differ. Even a correctly calculated estimate does not establish chronicity or exclude kidney damage with preserved filtration.
The 2021 CKD-EPI combined equation uses creatinine and cystatin C; the cystatin C-only equation listed by NIDDK is the 2012 CKD-EPI equation. A result labeled “cystatin C with eGFR” should not automatically be described as a 2021 combined result. Ordering two separate markers also does not guarantee that the laboratory will report the combined calculation. NIDDK: equation names and inputs.
A clinician may seek a combined estimate or measured GFR when accuracy near a drug-dosing cutoff matters. Most eGFR reports are indexed to a body-surface area of 1.73 m². For some medication decisions, especially when body size differs substantially from average, a non-indexed estimate in mL/min may be relevant. NIDDK: kidney function and drug dosing.
That calculation does not replace the drug label, clinical status, or prescriber judgment. Different medicines use different renal-function guidance. Cystatin C testing does not directly measure a medication level, guarantee prevention of toxicity, or determine whether a contrast study should proceed. Do not adjust a prescription on your own.
| Test | Question it addresses | Important limitation |
|---|---|---|
| Cystatin C with eGFR | Would a second filtration marker help clarify kidney function? | Confirm whether the report includes a cystatin C-only estimate. |
| Creatinine Test | What is the initial or ongoing creatinine-based estimate? | Muscle mass and other non-kidney influences matter. |
| Estimated Glomerular Filtration Rate with Creatinine and Cystatin C | Would a laboratory-calculated combined estimate help? | Remains an estimate; confirm reporting and specimen requirements. |
| Albumin Random Urine Test with Creatinine | Is albumin loss present in a spot urine sample? | Needs collection context and confirmation when abnormal. |
| Urinalysis Complete Test | Are other urinary abnormalities present? | Does not replace UACR or identify every cause. |
These tests answer different questions; they are not an instruction to order everything together. Check whether recent results already provide the information needed. Broader CKD complication testing belongs in a separate monitoring plan rather than being added automatically because cystatin C was ordered.
Read the instructions for the complete order. Fasting may depend on accompanying tests, and a blood order plus a urine order requires attention to both specimens. Tell the healthcare team about recent illness, major exercise, supplements, corticosteroids, and known thyroid disease. Follow your usual clinician-directed fluid plan rather than deliberately overhydrating.
There is no universal schedule for repeating cystatin C. A clinician may repeat testing to resolve an unexpected finding, assess a meaningful change, or support a specific decision. Long-term CKD surveillance still includes filtration and urine albumin assessment at a frequency appropriate to risk. A routine three- or six-month interval should not be applied to everyone.
It can add useful information when creatinine is affected by non-kidney factors, particularly muscle mass. The combined estimate generally improves average accuracy over creatinine alone. However, cystatin C has its own influences, and a clinician may prefer the less-affected marker or measured GFR when a major source of distortion is present.
It may reveal reduced filtration that a creatinine-based estimate misses in a particular person, but it does not reliably detect CKD “one stage sooner.” Kidney damage can also exist with preserved filtration. Evaluation still needs urine albumin, persistence, and clinical context rather than a promise that one marker always detects disease first.
No. A high concentration can support concern about reduced filtration, but interpretation includes the laboratory interval, equation, patient factors, and possible non-GFR influences. Chronic kidney disease also requires an appropriate persistent pattern or other evidence of chronicity. Rapidly changing results or illness may require assessment for an acute problem instead.
No. The combined equation uses the actual creatinine and cystatin C concentrations together with the other required variables. Do not calculate it by taking the arithmetic average of two reported eGFR values. Ask whether the laboratory reports a validated combined estimate and whether the measurements are appropriate to compare.
No. Filtration may remain preserved even when urine albumin or another marker identifies kidney damage. Structural or inherited kidney disease may also require information beyond blood markers. A reassuring cystatin C result therefore does not replace urine testing, earlier records, imaging when indicated, or investigation of persistent symptoms.
Not automatically. Body composition may make additional filtration information useful, but age or athletic activity alone does not establish a requirement for a particular test. The useful question is whether creatinine may be misleading and whether added precision would change interpretation or care. A clinician can help decide which measurement answers that question.
Adult equations should not be applied automatically to children. Pediatric and young-adult equations have different validated populations and requirements. Even near the transition to adult care, equation choice may matter for interpreting trends. Ask the treating clinician or laboratory which equation is appropriate rather than substituting an online adult calculator.
Ulta Lab Tests provides access to related laboratory testing where available. Choose the specific product with your clinical question in mind and confirm its current reporting and collection instructions. Coordinate with your healthcare professional so the results can inform care and so recent or already scheduled testing is not unnecessarily duplicated.
Seek prompt clinical assessment for a rapid deterioration in kidney results, markedly reduced urine output, or concerning new swelling. Severe breathlessness, chest pain, confusion, or fainting warrants urgent medical care. Do not wait for a routine cystatin C order to evaluate a possible acute kidney problem.
Cystatin C testing can strengthen filtration assessment when used with the appropriate equation and clinical context. Explore the linked testing options, confirm which result the order will provide, and review it with a qualified healthcare professional. For causes and the diagnostic process, read the CKD overview; for paired-result interpretation, use the eGFR and urine albumin guide.
Originally published: August 11, 2025 | Updated: September 20 2026
| Category | Tests |
|---|---|
| Main filtration marker | Cystatin C with eGFR |
| Comparison and combined estimation | Creatinine, eGFR with Creatinine and Cystatin C |
| Complementary urine assessment | Albumin Random Urine with Creatinine—UACR, Urinalysis Complete |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
